@prefix dct: .
@prefix this: .
@prefix sub: .
@prefix prov: .
@prefix pav: .
@prefix orcid: .
@prefix codebase: .
@prefix version: .
@prefix instance: .
@prefix process: .
@prefix np: .
@prefix rdfs: .
@prefix xsd: .
@prefix has-source: .
@prefix d: .
@prefix dv: .
@prefix dr: .
@prefix npx: .
sub:head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:publicationInfo;
a np:Nanopublication .
}
sub:assertion {
d:DB00242 dv:ddi-interactor-in dr:DB00242_DB01656 .
d:DB01656 dv:ddi-interactor-in dr:DB00242_DB01656 .
dr:DB00242_DB01656 dct:identifier "drugbank_resource:DB00242_DB01656";
dct:title "DDI between Cladribine and Roflumilast - Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as cladribine. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible."@en;
a dv:Drug-Drug-Interaction;
rdfs:label "DDI between Cladribine and Roflumilast - Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as cladribine. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible. [drugbank_resource:DB00242_DB01656]"@en .
}
sub:provenance {
sub:assertion has-source: dr:bio2rdf.dataset.drugbank.R3 .
}
sub:publicationInfo {
sub:signature.MCwCFFG_4BTkPCvG npx:hasPublicKey "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";
npx:hasSignature "MCwCFFG/4BTkPCvGhD+uwIkQKTYmFr4aAhQct9aUVlWXS+kqXMsmTrJ0bTaXTg==";
npx:signedBy instance: .
this: dct:created "2018-03-30T11:12:28.708+02:00"^^xsd:dateTime;
dct:license ;
npx:hasSignatureElement sub:signature.MCwCFFG_4BTkPCvG;
prov:wasGeneratedBy process: .
instance: prov:specializationOf codebase:;
prov:wasAttributedTo orcid:0000-0002-1267-0234 .
process: dct:identifier "3c184e6c-ceb8-4275-a679-71dfbdac2a11";
prov:used version:;
prov:wasAssociatedWith instance:;
prov:wasStartedBy orcid:0000-0002-1267-0234 .
version: dct:isVersionOf codebase:;
pav:version "eda7951a5f6c622c5d2132f50c3093138484a349";
prov:wasAttributedTo orcid:0000-0002-1267-0234 .
}